A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss

INTRODUCTION: The sodium-glucose cotransporter 2 inhibitor dapagliflozin and the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduce bodyweight via differing and complementary mechanisms. This post hoc analysis investigated the metabolic effects and baseline associations with bodyweigh...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Ther
Hlavní autoři: Pereira, Maria J., Lundkvist, Per, Kamble, Prasad G., Lau, Joey, Martins, Julian G., Sjöström, C. David, Schnecke, Volker, Walentinsson, Anna, Johnsson, Eva, Eriksson, Jan W.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Healthcare 2018
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6064580/
https://ncbi.nlm.nih.gov/pubmed/29949016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0449-6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky